PLUS1
0.82
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Atossa Therapeutics Inc | ATOS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 0.82 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.82 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.50 - 1.62 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.82 | USD |
Period:
Draw Mode:
Atossa Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 103.83M | 126.62M | 126.57M | $ - | $ - | -0.18 | -4.30 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | 0.40% |
Atossa Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATOS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.8066 | 0.85 | 0.721 | 0.8076848 | 454,854 | 0.0134 | 1.66% |
| 1 Month | 0.5565 | 1.00 | 0.55 | 0.7930287 | 761,013 | 0.2635 | 47.35% |
| 3 Months | 0.8558 | 1.00 | 0.50 | 0.7263734 | 576,851 | -0.0358 | -4.18% |
| 6 Months | 0.959 | 1.15 | 0.50 | 0.8445561 | 559,711 | -0.139 | -14.49% |
| 1 Year | 1.23 | 1.62 | 0.50 | 1.10 | 1,157,869 | -0.41 | -33.33% |
| 3 Years | 1.46 | 9.80 | 0.50 | 3.33 | 5,429,361 | -0.64 | -43.84% |
| 5 Years | 7.20 | 10.68 | 0.50 | 3.63 | 3,733,618 | -6.38 | -88.61% |
Atossa Therapeutics Description
| Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. |